(Q37935596)

25 August 2017

1 reference

title

Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity (English)

1 reference

25 August 2017

main subject

arterial hypertension

0 references

heart failure

0 references

author name string

Rajesh Gupta

series ordinal

1

1 reference

25 August 2017

Michael L Maitland

series ordinal

2

1 reference

25 August 2017

language of work or name

1 reference

1 December 2011

1 reference

Current Hypertension Reports

25 August 2017

published in

1 reference

25 August 2017

volume

13

1 reference

25 August 2017

issue

6

1 reference

25 August 2017

page(s)

430-435

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-011-0229-4

25 August 2017

exact match

0 references

cites work

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Home blood-pressure monitoring in patients receiving sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Selectivity and therapeutic inhibition of kinases: to be or not to be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-011-0229-4

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21931979

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11906-011-0229-4

1 reference

25 August 2017

1 reference